Country or Global license ContactDavid Cunningham,
Account Manager,
781-972-5472 cunningham@
healthtech.com
Length 116 pages
Date published October 2005
Additional info Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.
Hematological Cancer Therapeutics:
Pipelines and Competition
Hermann A.M. Mucke, Ph.D.
New Page 1
Figure
1.1. B-Cell Cancers by Cell Development
Figure 1.2. Cancer Deaths by Gender, United States, 2004
Figure 1.3. The “Philadelphia Chromosome” Translocation
Figure 3.1. Prevention of Methylation-Induced Gene Silencing through
Inhibition of DNA Methyltransferase Using Nucleoside Analogs
Figure 3.2. DNA Methyltransferase and Histone Deacetylase Enzymes
Synergize to Prevent Access of Transcription Factors to DNA by Condensing
Chromatin
Figure 4.1. The Chemical Structure of Thalidomide and Lenalidomide
Figure 4.2. Potential Antigen Targets for Immunotherapy in Leukemia
Figure 4.3. Activation and Proliferation of Patient T Cells by Autologous
Chronic Lymphocytic Leukemia Cells before (Pre Rx) and 6 Months after
(Post Rx) Infusion of Ad-CD154–Transduced CLL Cells
Table 1.1. Incidence and Annual Deaths from Main Types of Leukemias,
United States, 2004
Table 3.1. FDA-Approved Monoclonal Antibody Drugs for Leukemia
and Lymphomas
Table 3.2. Rituxan Adoption Rates in Non–Hodgkin’s
Lymphoma and Chronic Lymphocytic Leukemia
Table 5.1. Drug Candidates with Submitted New Drug Applications
or in Confirmed Active Phase III for Hematological Cancers
Table 5.2. New Chemical Entities in Top Clinical Stages I/II or
II for Hematological Cancers
Table 5.3. Monoclonal Antibodies, Antisense Oligonucleotides, Cell
Therapies, and Immunotoxins in Top Clinical Stages I, I/II, or
II for Hematological Cancers
"CHI's Insight
Pharma Reports are
a cost-effective and reliable source
of information about the markets
we serve. The cost
for us to conduct
this kind of business
research on our
own would be
prohibitive. CHI's
Insight Pharma
Reports allow us to
keep on top of
developments in
this rapidly moving
field."
--Donald N. Halbert, Ph.D., EVP of R&D, Iconix Biosciences
A division of
Cambridge
Healthtech Institute
CHI's Insight Pharma Reports, a division of Cambridge Healthtech Institute
| 250 First Avenue | Needham, MA 02494
For more information, email
Rose LaRaia at rlaraia@healthtech.com or call 781-972-5444
